4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0000950170-25-110775
Chief R&D Officer sold 725 shares at $26.59 ($19,278)
From the SEC's structured data for this filing
Trades in this filing
Zalevsky Jonathan · Chief R&D Officer
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-08-19 | Sale : show line 1 in the form | −725 | $26.59 | $19,278 | 19,668 | D |
| Open-market sales · 725 sh · avg $26.59 · $19,278 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-08-19 | Grant or award : show line 2 in the form Stock Option | +16,666 | 16,666 | D |
Loading xslF345X05/ownership.xml…